Sesen Bio Inc.

(SESN) Trade

By |

Profile

Sesen Bio Inc is a late-stage clinical company engaged in next-generation antibody-drug conjugate therapies for the treatment of cancer-based on the company's Targeted Protein Therapeutics platform. The company's lead program, Vicinium, also known as VB4-845, is currently in a Phase 3 registration trial, the VISTA Trial, for the treatment of high-grade non-muscle invasive bladder cancer.

Contact Information

Website: www.sesenbio.com
Email: monique@thrustsc.com
Main Phone: +1 617 444-8550
Address: 245 First Street
Address 2: Suite 1800
State: MA
City / Town: Cambridge
Country: USA
Postal Code: 02142

Issuer Information

Exchange: NSD
CEO: Thomas R. Cannell
Employees: 25
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

Profile

Sesen Bio Inc is a late-stage clinical company engaged in next-generation antibody-drug conjugate therapies for the treatment of cancer-based on the company's Targeted Protein Therapeutics platform. The company's lead program, Vicinium, also known as VB4-845, is currently in a Phase 3 registration trial, the VISTA Trial, for the treatment of high-grade non-muscle invasive bladder cancer.

Contact Information

Website: www.sesenbio.com
Email: monique@thrustsc.com
Main Phone: +1 617 444-8550
Address: 245 First Street
Address 2: Suite 1800
State: MA
City / Town: Cambridge
Country: USA
Postal Code: 02142

Issuer Information

Exchange: NSD
CEO: Thomas R. Cannell
Employees: 25
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

$ 0.80 $ 0.0041 (0.51%)
Last Price 0.80 Change $ 0.0041 Change % 0.51 Tick N/A
Bid 0.79 Bid Size 1,000.00 Ask 0.82 Ask Size 900.00
Open 0.81 High 0.82 Low 0.77 Prev Close 0.80
Last Trade Volume 1 mi 52 Wk Hi 2.53 52 Wk Low 0.38
Market Cap 88.8 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 110,416,298.00 EPS (TTM) -0.82 PE Ratio N/A Exchange NSD
  Last 3 Mo Last 12 Mo
Number of Insider Trades 0 1
Number of Buys 0 1
Number of Sells 0 0
Net Activity 0 105000
Last 10 Buys Shares
N/A 0
Last 10 Sell Shares
John J. Mccabe 1,000
Abbie C. Celniker 1,000
Noubar B. Afeyan 1,000
Noubar B. Afeyan 1,000
Noubar B. Afeyan 1,000
Noubar B. Afeyan 1,000
Noubar B. Afeyan 1,000
Noubar B. Afeyan 1,000
Noubar B. Afeyan 1,000
Noubar B. Afeyan 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 3.5 3.5 2 3.5
Low Target Price Estimate 3.5 3.5 2 3.5
Mean Target Price Estimate 3.5 3.5 2 3.5
Standard Deviation 0 0 0 0
Date of Most Recent Estimate 05/22/18 05/22/18 03/20/18 05/22/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 1 1 1 0
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1 1 1 0